Rapamune 1 mg/ml solución oral    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
158Tuberous sclerosis1

158. Tuberous sclerosis    [ 100 clinical trials,   62 drugs,   (DrugBank: 16 drugs),   35 drug target genes,   115 drug target pathways]
Searched query = "Tuberous sclerosis", "Tuberous sclerosis complex"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 100 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2011-006308-12-ES
(EUCTR)
16/07/201229/03/2012Clinical trial in patients with tuberous sclerosis for the study of the effects of topical rapamycin in reducing facial tumors associated with the disease ..phase II clinical trial, to study the efficacy and safety of topical rapamycin in reducing facial angiofibromas. Facial tumors (angiofibromas) associated with tuberous sclerosis complex.;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]Trade Name: Rapamune 1 mg/ml solución oral
INN or Proposed INN: RAPAMUNE
Fundación Investigación Hospital Ramón y CajalNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Phase 2Spain